The company recently conducted a review of clinical data from four studies that it had conducted wherein 582 women were treated for autoimmune diseases or fibromyalgia syndrome over three to six months with one of five different low daily doses of oral interferon or placebo.
This review found that a significantly greater proportion of women given two specific doses of oral interferon experienced at least a 5% weight loss, compared to the women given placebo. This surprising benefit occurred in the women given oral interferon without a significant increase in adverse events.
Peter Mueller, COO of ABI, said: “While we clearly need to conduct additional studies to establish the efficacy of low-dose oral interferon as a weapon against the growing obesity pandemic, the filing of this patent could be enormously valuable to Amarillo Biosciences in the long term.”